Please assess the completion status of the following clinical trial:

Trial Title: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Be ≥12 years of age.~2. Weigh ≥ 40 kg.~3. Be a recipient of stem cell or solid organ transplantation.~4. Have documented CMV infection in blood or plasma, with a screening value of ≥1,000 DNA copies/mL.~5. Have a current CMV infection that is resistant (known CMV genetic mutations) or refractory (clinical failure to respond) to treatment with ganciclovir/valganciclovir and/or foscarnet.~6. If female, be either postmenopausal, surgically sterile, or have a negative pregnancy test prior to randomization.~7. Be able to swallow tablets.~8. If adult, provide written informed consent. If child (age \<18 years), have a parent/legal guardian who is willing and able to provide written informed consent (with assent from the child when appropriate).~9. Be assessed by the investigator to determine whether prophylaxis for non-CMV herpesvirus infections (e.g., herpes simplex virus \[HSV type 1 and type 2\] and varicella zoster virus \[VZV\]) is appropriate according to institutional guidelines or standard practices, keeping in mind that maribavir is not active in vitro against these viruses.~Exclusion Criteria~1. Be receiving any other anti-CMV agent(s).~2. Have a current CMV infection that is considered resistant or refractory due to inadequate adherence to prior oral anti-CMV treatment.~3. Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the time of enrollment.~4. Have severe hepatic impairment.~5. Require mechanical ventilation or vasopressors for hemodynamic support at the time of enrollment.~6. Have expected survival less than 6 weeks.~7. Be pregnant or breastfeeding.~8. Other clinically significant medical or surgical condition.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Maribavir 400 mg twice daily (Type: EXPERIMENTAL): None
- Maribavir 800 mg twice daily (Type: EXPERIMENTAL): None
- Maribavir 1200 mg twice daily (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).